Interview with Wolfgang Söhngen, CEO, Paion
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
Address: Georg-Glock-Straße 8, 40474 Düsseldorf,Germany
Tel: 0211 – 5 86 01-00
Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of therapeutic, corrective and aesthetic solutions in dermatology. Its expertise spans a broad spectrum of skin, hair and nail diseases. Founded in 1981, Galderma is a joint venture between Nestlé and L’Oréal and employs close to 3.000 people. The company, headed by President & CEO Humberto C. Antunes, has wholly-owned affiliates in 31 countries and a worldwide network of exclusive sales agents. The parent company is based in Lausanne, Switzerland, with Corporate Services in Paris-La Défense, France. In 2008, sales reached 854 million euros, an increase of + 22.4%* over 2007.To drive sustained growth, Galderma invests around 20 percent of revenues in innovation for the development of drugs and other medical solutions which are sourced internally from its own research activities or from partnerships. The R&D staff operates out of 3 specialized sites in the USA, France and Japan.With products sold in more than 65 countries and promoted by a sales force of around 1.000 representatives, Galderma is providing a wide range of innovative medical solutions meeting the highest standards of safety and efficacy. Committed to the future of dermatology, Galderma’s ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meetings the needs of dermatology patients and physicians.
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the…
You have a wide professional experience that goes from financial adviser to biotechnology entrepreneur, passing through software business and politics. How will all of those different experiences enable you to…
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
What role does the German Pharmaceutical Industry Association (BPI) play for the German pharmaceutical industry? BPI is the oldest industry association of the German pharmaceutical industry, dating back to 1951.…
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for…
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
See our Cookie Privacy Policy Here